Efficacy of Reslizumab in Older Patients (≥65 years) with Asthma and Elevated Blood Eosinophils: Results from a Pooled Analysis of Two Phase 3, Placebo-Controlled Trials
Saturday, March 5, 2016: 2:30 PM
Room 502B (Convention Center)
David I. Bernstein, MD FAAAAI, , ,
Rationale: Reslizumab was recently shown to improve multiple measures of asthma control in patients aged 12-75 years with inadequately controlled asthma and blood eosinophils ≥400cells/µL (Castro et al., Lancet Resp Med. 2015). The influence of older age (≥65 years) on reslizumab efficacy is unknown.

Methods: Pooled results from two duplicate, 52-week, placebo-controlled studies of reslizumab (3mg/kg IV Q4W) for asthma were stratified by age: 18-64 years (‘younger adults’) and ≥65 years. Efficacy assessments included: rate of clinical asthma exacerbations (CAE) and change from baseline in FEV1, ACQ-7 and AQLQ.

Results: 77 patients were ≥65 and 851 patients were 18-64 years old. The reduction in CAE frequency for patients ≥65 years was 67% (95% CI:29%, 85%) versus 53% in younger adults (95% CI:40%, 64%). The mean change in FEV1, ACQ-7 and AQLQ for reslizumab relative to placebo at 52 weeks in patients ≥65 and in younger adults was: 150mL (95% CI:17, 283) and 126mL (95% CI:67, 184); -0.997 (95% CI:-1.447, -0.547) and -0.305 (95% CI:-0.438, -0.173); and 0.876 (95% CI:0.417, 1.336) and 0.316 (95% CI:0.169, 0.462), respectively.

Conclusions: Reslizumab was effective at reducing the frequency of asthma exacerbations, and in improving lung function, asthma control and quality of life in patients ≥65 years old. The observed improvements in this subgroup were numerically larger than for younger adults, with changes in ACQ-7 and AQLQ both exceeding the minimally important difference for the measure.